Family History, Genetic Testing, and Clinical Risk Prediction: Pooled Analysis of CHEK2*1100delC in 1,828 Bilateral Breast Cancers and 7,030 Controls
Open Access
- 1 January 2009
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 18 (1) , 230-234
Abstract
If breast cancers arise independently in each breast the odds ratio (OR) for bilateral breast cancer for carriers of CHEK2*1100delC should be ∼5.5, the square of the reported OR for a first primary (OR, 2.34). In the subset of bilateral cases with one or more affected relatives, the predicted carrier OR should be ∼9. We have tested these predictions in a pooled set of 1,828 cases with 2 primaries and 7,030 controls from 8 studies. The second primary OR for CHEK2*1100delC carriers was 6.43 (95% confidence interval, 4.33-9.56; P < 0.0001), significantly greater than the published estimate for a first primary (P < 0.001) but consistent with its square. The predicted increase in carrier OR with increasing numbers of affected relatives was seen using bilateral cases from the UK (Ptrend = 0.0003) and Finland (Ptrend = 0.37), although not using those from the Netherlands and Russia (P = 0.001 for heterogeneity between countries). Based on a standard genetic model, we predict lifetime risks for CHEK2*1100delC carrier and noncarrier daughters of bilateral breast cancer cases of 37% and 18%, respectively. Our results imply that clinical management of the daughter of a woman with bilateral breast cancer should depend on her CHEK2*1100delC carrier status. This and other moderate penetrance breast cancer susceptibility alleles, together with family history data, will thus identify increasing numbers of women at potentially very high risk. Before such predictions are accepted by clinical geneticists, however, further population-based evidence is needed on the effect of CHEK2*1100delC and other moderate penetrance alleles in women with a family history of breast cancer. (Cancer Epidemiol Biomarkers Prev 2009;18(1):230–4)Keywords
This publication has 28 references indexed in Scilit:
- Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33Proceedings of the National Academy of Sciences, 2008
- The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensionsBritish Journal of Cancer, 2008
- Genome-wide association study identifies novel breast cancer susceptibility lociNature, 2007
- A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancerNature Genetics, 2007
- Identification of women with an increased risk of developing radiation-induced breast cancer: a case only studyBreast Cancer Research, 2007
- A common coding variant in CASP8 is associated with breast cancer riskNature Genetics, 2007
- A recurrent mutation in PALB2 in Finnish cancer familiesNature, 2007
- PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility geneNature Genetics, 2006
- The BOADICEA model of genetic susceptibility to breast and ovarian cancerBritish Journal of Cancer, 2004
- Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutationsNature Genetics, 2002